Zoetis (NYSE:ZTS) had its price objective hoisted by equities research analysts at BMO Capital Markets to $78.00 in a report released on Tuesday, January 9th, The Fly reports. The brokerage presently has a “market perform” rating on the stock. BMO Capital Markets’ price target would suggest a potential upside of 0.36% from the stock’s current price.
A number of other research firms have also weighed in on ZTS. Zacks Investment Research lowered shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, January 6th. Cantor Fitzgerald set a $85.00 target price on shares of Zoetis and gave the stock a “buy” rating in a report on Tuesday, December 26th. Citigroup upgraded shares of Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 price objective for the company in a research note on Thursday, January 4th. Craig Hallum reiterated a “buy” rating and issued a $85.00 price objective (up previously from $77.00) on shares of Zoetis in a research note on Tuesday, January 2nd. Finally, Morgan Stanley upgraded shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price objective for the company in a research note on Wednesday, November 29th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $73.72.
Shares of Zoetis (NYSE:ZTS) opened at $77.72 on Tuesday. The company has a market cap of $37,389.63 and a price-to-earnings ratio of 40.91. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. Zoetis has a 1 year low of $52.00 and a 1 year high of $80.13.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.02. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The business’s revenue was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.52 EPS. equities research analysts expect that Zoetis will post 2.36 EPS for the current fiscal year.
Large investors have recently made changes to their positions in the business. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Zoetis during the 4th quarter valued at $108,000. Northwestern Mutual Wealth Management Co. raised its position in shares of Zoetis by 16.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after buying an additional 230 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in shares of Zoetis during the 3rd quarter valued at $114,000. Harfst & Associates Inc. raised its position in shares of Zoetis by 16.1% during the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after buying an additional 260 shares in the last quarter. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in shares of Zoetis by 251.9% during the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after buying an additional 1,360 shares in the last quarter. 93.17% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This story was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/02/zoetis-zts-price-target-increased-to-78-00-by-analysts-at-bmo-capital-markets.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.